CervoMed to Showcase Groundbreaking Research Findings
BOSTON, March 25, 2025 – CervoMed Inc. (NASDAQ: CRVO), a pioneering clinical-stage company dedicated to addressing age-related neurologic disorders, is poised to make waves in the medical community. The company is set to deliver a noteworthy oral presentation at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™), taking place from April 1 to April 5, 2025. This prestigious event will be held in Vienna, Austria, where leading experts in the field will gather to discuss the latest advancements in neurology.
Details of the Upcoming Presentation
CervoMed's presentation will center on critical findings from the Extension Phase of the RewinD-LB Phase 2b study. The focus will be on their investigational drug, neflamapimod, which is currently being studied for its efficacy in treating dementia with Lewy bodies (DLB). This condition represents a significant challenge in geriatric care and understanding its treatment options is crucial for improving the lives of those affected.
Key Presentation Insights
The presentation will feature the following important details:
Abstract Title: Efficacy and safety results of the RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)
Format: Oral Presentation
Presenters: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB Study along with Stephen Gomperts, MD, PhD, an Associate Professor of Neurology at Harvard Medical School and Director of the Lewy Body Dementia Unit at Massachusetts General Hospital.
Session Name: Advances in PD, LBD, and MSA Drug Development
Scheduled Presentation Date: Saturday, April 5th, 2025, from 18:25 to 18:40 PM CET
Exploring Neflamapimod
Neflamapimod is an exciting oral medication that belongs to a class of small molecules designed to penetrate the brain effectively. It specifically inhibits the activity of p38 mitogen-activated protein kinase alpha, a pathway implicated in the neurodegenerative processes associated with diseases like DLB. This innovative approach has the potential to address synaptic dysfunction, which is reversible in nature, an exciting aspect for those facing degenerative conditions.
Understanding CervoMed’s Mission
CervoMed is committed to harnessing the power of science to transform neurologic disorder treatment. Their ongoing efforts with neflamapimod showcase their dedication to providing solutions for patients dealing with debilitating conditions, particularly as the population ages. Such advancements could offer hope where few options currently exist, and the upcoming conference provides an invaluable platform to share this knowledge and insights with peers in the industry.
Opportunities for Investors
CervoMed recognizes the importance of engaging with investors who are interested in innovative health solutions. The details of the conference will be made available in the Investor section of CervoMed’s website soon after the presentation.
Connect with CervoMed
For further inquiries, please reach out to: PJ Kelleher of LifeSci Advisors at Investors@cervomed.com or via phone at 617-430-7579.
Frequently Asked Questions
What is the primary focus of CervoMed?
CervoMed primarily focuses on developing innovative treatments for age-related neurologic disorders.
What is the significance of neflamapimod?
Neflamapimod aims to treat synaptic dysfunction related to dementia with Lewy bodies, potentially improving patient outcomes.
When and where will CervoMed present?
CervoMed will present at the AP/PD conference in Vienna, Austria, from April 1 to April 5, 2025.
Who will be presenting on behalf of CervoMed?
John Alam, CEO of CervoMed, and Dr. Stephen Gomperts will lead the presentation.
How can investors stay updated on CervoMed's developments?
Investors can visit the Investor section on CervoMed's website for updates following the presentation.
